Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies

International Journal of Cardiology

Volumn 221, Issue , 2016, Pages 1073-1080

  Bielecka Dabrowa, Agata ^a   Sakowicz, Agata ^a   Misztal, Małgorzata ^b   von Haehling, Stephan ^c   Ahmed, Ali ^d   Pietrucha, Tadeusz ^a   Rysz, Jacek ^a   Banach, Maciej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Biomarkers; Dilated cardiomyopathy; Heart failure with preserved ejection fraction; Heart failure with reduced ejection fraction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; AMINOBUTYRIC ACID DERIVATIVE; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GENETIC MARKER; NOS3 PROTEIN, HUMAN; SACUBITRIL PLUS VALSARTAN; SDC4 PROTEIN, HUMAN; SYNDECAN 4; TETRAZOLE DERIVATIVE; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CYP27B1 GENE; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IL 6 GENE; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; NOS3 GENE; PATHOPHYSIOLOGY; PPAR GAMMA GENE; PRIORITY JOURNAL; TGF BETA GENE; TNF ALPHA GENE; AGED; COMPLICATION; DRUG EFFECTS; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; HEART MUSCLE ISCHEMIA; HEART STROKE VOLUME; MIDDLE AGED; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; CARDIOMYOPATHY, DILATED; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, SINGLE NUCLEOTIDE; STROKE VOLUME; SYNDECAN-4; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84978648903     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.07.150     Document Type: Article

References (44)

1. [1] O'Meara, E., Thibodeau-Jarry, N., Ducharme, A., Rouleau, J.L., The epidemic of heart failure: a lucid approach to stemming the rising tide. Can. J. Cardiol. 30:12 Suppl. (2014), S442–S454.
2. [2] Cheng, J.M., Akkerhuis, K.M., Battes, L.C., Vark, L.C., Hillege, H.L., Paulus, W.J., Boersma, E., Kardys, I., Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur. J. Heart Fail. 15 (2013), 1350–1362.
3. [3] Martos, R., Baugh, J., Ledwidge, M., et al. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur. J. Heart Fail. 11 (2009), 191–197.
4. [4] Goletti, S., Gruson, D., Personalized risk assessment of heart failure patients: more perspectives from transforming growth factor super-family members. Clin. Chim. Acta 443 (2015), 94–99.
5. [5] Bayes-Genis, A., Ordonez-Llanos, J., Multiple biomarker strategies for risk stratification in heart failure. Clin. Chim. Acta 30:443 (2015), 120–125.
6. [6] Wilke, R.A., Simpson, R.U., Mukesh, B.N., Bhupathi, S.V., Dart, R.A., Ghebranious, N.R., McCarty, C.A., Genetic variation in CYP27B1 is associated with congestive heart failure in patients with hypertension. Pharmacogenomics 10:11 (2009), 1789–1797.
7. [7] Bloch, K.D., Janssens, S., Cardiomyocyte-specific overexpression of nitric oxide synthase 3: impact on left ventricular function and myocardial infarction. Trends Cardiovasc. Med. 15 (2005), 249–253.
8. [8] Bielecka-Dabrowa, A., Michalska-Kasiczak, M., Gluba, A., Rysz, J., Banach, M., Biomarkers and echocardiographic predictors of myocardial dysfunction in patients with hypertension. Circulation, 130(Suppl. 2), 11/2014, A12171.
9. [9] Bielecka-Dabrowa, A., Michalska-Kasiczak, M., Gluba, A., Ahmed, A., von Healing, S., Gerdts, E., Rysz, J., Banach, M., Biomarkers and echocardiographic predictors of myocardial dysfunction in patients with hypertension. Sci. Rep., 5, 2015 Mar 9, 8916, 10.1038/srep08916.
10. [10] Bielecka-Dabrowa, Z., Gluba-Brzózka, A., Michalska-Kasiczak, M., Misztal, M., Rysz, J., Banach, M., The multi-biomarker approach for heart failure in patients with hypertension. Int. J. Mol. Sci. 16 (2015), 1–x, 10.3390/ijms160x000x.
11. [11] Gluba, A., Bielecka-Dabrowa, A., Mikhailidis, D.P., Wong, N.D., Franklin, S.S., Rysz, J., Banach, M., An update on biomarkers of heart failure in hypertensive patients. J. Hypertens. 30:9 (2012), 1681–1689.
12. [12] Bielecka-Dabrowa, A., von Haehling, S., Aronow, W.S., Ahmed, M.I., Rysz, J., Banach, M., Heart failure biomarkers in patients with dilated cardiomyopathy. Int. J. Cardiol. 68:3 (2013), 2404–2410.
13. [13] Lang, R.M., Bierig, M., Devereux, R.B., Flachskampf, F.A., Foster, E., Pellikka, P.A., Picard, M.H., Roman, M.J., Seward, J., Shanewise, J., Solomon, S., Spencer, K.T., St John Sutton, M., Stewart, W., American Society of Echocardiography's Nomenclature and Standards Committee, Task Force on Chamber Quantification, American College of Cardiology Echocardiography Committee, American Heart Association, European Association of Echocardiography, European Society of Cardiology, Recommendations for chamber quantification. Eur. J. Echocardiogr. 7:2 (2006), 79–108.
14. [14] The Criteria Committee of the New York Heart Association, Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. nineth ed., 1994, Little, Brown & Co., Boston, 253–256.
15. [15] Modification of Diet in Renal Disease Study Group, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann. Intern. Med. 130:6 (1999), 461–470.
16. [16] Paulus, W.J., Tschöpe, C., A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 62:4 (2013), 263–271.
17. [17] Putko, B.N., Wang, Z., Lo, J., Anderson, T., Becher, H., Dyck, J.R., Kassiri, Z., Oudit, G.Y., Alberta HEART Investigators, Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology. PLoS One, 9(6), 2014; 12, e99495.
18. [18] Westermann, D., Lindner, D., Kasner, M., et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ. Heart Fail. 4 (2011), 44–52.
19. [19] Kuwahara, F., Kai, H., Tokuda, K., et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106 (2002), 130–135.
20. [20] Murdoch, C.E., Chaubey, S., Zeng, L., et al. Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through pro-inflammatory effects and endothelial-mesenchymal transition. J. Am. Coll. Cardiol. 63 (2014), 2734–2741.
21. [21] Fleenor, B.S., Marshall, K.D., Rippe, C., Seals, D.R., Replicative aging induces endothelial to mesenchymal transition in human aortic endothelial cells: potential role of inflammation. J. Vasc. Res. 49 (2012), 59–64.
22. [22] Kim, M., Choi, S.H., Jin, Y.B., et al. The effect of oxidized low-density lipoprotein (ox-LDL) on radiation-induced endothelial-to-mesenchymal transition. Int. J. Radiat. Biol. 89 (2013), 356–363.
23. [23] Lindner, D., Zietsch, C., Tank, J., et al. Cardiac fibroblasts support cardiac inflammation in heart failure. Basic Res. Cardiol., 109, 2014, 428.
24. [24] Van Linthout, S., Miteva, K., Tschope, C., Crosstalk between fibroblasts and inflammatory cells. Cardiovasc. Res. 102 (2014), 258–269.
25. [25] Javed, Q., Murtaza, I., Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure. Heart Lung Circ. 22 (2013), 323–327.
26. [26] Menazza, S., Aponte, A., Sun, J., Gucek, M., Steenbergen, C., Murphy, E., Molecular signature of nitroso-redox balance in idiopathic dilated cardiomyopathies. J. Am. Heart Assoc., 4(9), 2015 Sep 22, e002251, 10.1161/JAHA.115.002251.
27. [27] Gopal, D.M., Sam, F., New and emerging biomarkers in left ventricular systolic dysfunction — insight into dilated cardiomyopathy. J. Cardiovasc. Transl. Res. 6:4 (2013), 516–527.
28. [28] Kose, M., Akpinar, T.S., Bakkaloglu, O.K., Tufan, A., Sumnu, A., Emet, S., Kocaaga, M., Erk, O., Kayacan, M.S., Güler, K., Demirel, A.S., Association of genetic polymorphisms with endothelial dysfunction in chronic heart failure. Eur. Rev. Med. Pharmacol. Sci. 18:12 (2014), 1755–1761.
29. [29] Binkley, P.F., Nunziatta, E., Liu-Stratton, Y., Cooke, G., A polymorphism of the endothelial nitric oxide synthase promoter is associated with an increase in autonomic imbalance in patients with congestive heart failure. Am. Heart J. 149:2 (2005), 342–348.
30. [30] Tsutamoto, T., Wada, A., Maeda, K., Mabuchi, N., Hayashi, M., Tsutsui, T., Ohnishi, M., Fujii, M., Matsumoto, T., Yamamoto, T., Wang, X., Asai, S., Tsuji, T., Tanaka, H., Saito, Y., Kuwahara, K., Nakao, K., Kinoshita, M., Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 38:5 (2001), 1485–1490.
31. [31] Polyakova, V., Loeffler, I., Hein, S., Miyagawa, S., Piotrowska, I., Dammer, S., Risteli, J., Schaper, J., Kostin, S., Fibrosis in endstage human heart failure: severe changes in collagen metabolism and MMP/TIMP profiles. Int. J. Cardiol. 151:1 (2011; 18), 18–33.
32. [32] Kaufman, B.D., Videon, N., Zhang, X., Harris, M.A., Shaddy, R.E., Goldmuntz, E., Procollagen type III amino-terminal propeptide: a serum biomarker of left ventricular remodelling in paediatric dilated cardiomyopathy. Cardiol. Young 25:2 (2015), 228–236.
33. [33] Strand, M.E., Herum, K.M., Rana, Z.A., Skrbic, B., Askevold, E.T., Dahl, C.P., Vistnes, M., Hasic, A., Kvaløy, H., Sjaastad, I., Carlson, C.R., Tønnessen, T., Gullestad, L., Christensen, G., Lunde, I.G., Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan-4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure-overloaded heart. FEBS J. 280:10 (2013), 2228–2247.
34. [34] Takahashi, R., Negishi, K., Watanabe, A., Arai, M., Naganuma, F., Ohyama, Y., Kurabayashi, M., Serum syndecan-4 is a novel biomarker for patients with chronic heart failure. J. Cardiol. 57 (2011), 325–332.
35. [35] Ma, X., Ouyang, P., Zhang, Z., Lai, W., Xu, D., Changes and clinical significance of serum level of syndecan-4 protein in patients with chronic congestive heart failure. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 29:8 (2013), 866–869.
36. [36] Carlsen, C.M., Bay, M., Kirk, V., Gotze, J.P., Kober, L., Nielsen, O.W., Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal probrain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study. Eur. J. Heart Fail. 14 (2012), 240–247.
37. [37] Matsui, Y., Ikesue, M., Danzaki, K., Morimoto, J., Sato, M., Tanaka, S., Kojima, T., Tsutsui, H., Uede, T., Syndecan-4 prevents cardiac rupture and dysfunction after myocardial infarction. Circ. Res. 108:11 (2011 27), 1328–1339.
38. [38] Behnes, M., Hoffmann, U., Lang, S., Weiss, C., Ahmad-Nejad, P., Neumaier, M., Borggrefe, M., Brueckmann, M., Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure. Clin. Res. Cardiol. 100:4 (2011), 335–342.
39. [39] Khan, S., Joyce, J., Margulies, K.B., Tsuda, T., Enhanced bioactive myocardial transforming growth factor-β in advanced human heart failure. Circ. J. 78:11 (2014), 2711–2718.
40. [40] Li, P., Wang, D., Lucas, J., Oparil, S., Xing, D., Cao, X., Novak, L., Renfrow, M.B., Chen, Y.F., Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ. Res. 102 (2008), 185–192.
41. [41] Lim, H., Zhu, Y.Z., Role of transforming growth factor-beta in the progression of heart failure. Cell. Mol. Life Sci. 63:22 (2006), 2584–2596.
42. [42] Szelényi, Z., Fazakas, Á., Szénási, G., Kiss, M., Tegze, N., Fekete, B.C., Nagy, E., Bodó, I., Nagy, B., Molvarec, A., Patócs, A., Pepó, L., Prohászka, Z., Vereckei, A., Inflammation and oxidative stress caused by nitric oxide synthase uncoupling might lead to left ventricular diastolic and systolic dysfunction in patients with hypertension. J. Geriatr. Cardiol. 12:1 (2015), 1–10.
43. [43] Purnomo, Y., Piccart, Y., Coenen, T., Prihadi, J.S., Lijnen, P.J., Oxidative stress and transforming growth factor-β1-induced cardiac fibrosis. Cardiovasc. Hematol. Disord. Drug Targets 13:2 (2013), 165–172.
44. [44] Lefkowitz, M.P., LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure. BMC Pharmacol. Toxicol., 16(Suppl. 1), 2015, A1.